StockNews.AI
CYBN
StockNews.AI
103 days

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

1. Cybin Inc. received a patent for the CYB003 program in MDD. 2. The patent grants exclusivity until 2041, boosting market competitiveness.

2m saved
Insight
Article

FAQ

Why Bullish?

The patent provides a strong competitive edge, akin to earlier biotech patents that boosted stocks significantly post-approval.

How important is it?

The patent enhances CYBN's product pipeline and market position, likely attracting investor interest.

Why Long Term?

The exclusivity until 2041 ensures prolonged market advantage, benefiting CYBN's revenue potential.

Related Companies

MDGLATAIPSIL
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,291,499 in support of its CYB003 program in MDD. The patent, which is expected to provide exclusivity until 2041, includes cla.

Related News